EICHORPublic-registry site landscape for NCT07705555, “A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)”, a Diabetic Retinopathy study sponsored by Merck Sharp & Dohme LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07705555 (registry record) |
| Study title | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) |
| Official title | A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME) |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition(s) | Diabetic Retinopathy; Macular Edema |
| Phase | PHASE3 |
| Listed sites | 0 |
Patient-friendly overview of this study: eichor.com/study/NCT07705555.
Eichor generates a preliminary site-risk snapshot for NCT07705555 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetic Retinopathy trials
More from Merck Sharp & Dohme LLC
← Eichor home · All tracked trials · Diabetic Retinopathy studies · Weekly briefs
